key: cord-0735330-bqemz1eu
authors: Zheng, J.; Zhang, Y.; Liu, Y.; Baird, D.; Liu, X.; Wang, L.; Zhang, H.; Davey Smith, G.; Gaunt, T.
title: Multi-omics study revealing tissue-dependent putative mechanisms of SARS-CoV-2 drug targets on viral infections and complex diseases
date: 2020-05-11
journal: nan
DOI: 10.1101/2020.05.07.20093286
sha: c4a113578de7f9b2c083980eda1b5580465ce2cf
doc_id: 735330
cord_uid: bqemz1eu

Drug target prioritisation for new targets and drug repurposing of existing drugs for COVID-19 treatment are urgently needed for the current pandemic. Here we pooled 353 candidate drug targets of COVID-19 from clinical trial registries and the literature and estimated their putative causal effects in 11 SARS-CoV-2 related tissues on 622 complex human diseases. By constructing a disease atlas of drug targets for COVID-19, we prioritise 726 target-disease associations as evidence of causality using robust Mendelian randomization (MR) and colocalization evidence (http://epigraphdb.org/covid-19/ctda/). Triangulating these MR findings with historic drug trial information and the druggable genome, we ranked and prioritised three genes DHODH, ITGB5 and JAK2 targeted by three marketed drugs (Leflunomide, Cilengitide and Baricitinib) which may have repurposing potential with careful risk assessment. This study evidences the value of our integrative approach in prioritising and repurposing drug targets, which will be particularly applicable when genetic association studies of COVID-19 are available in the near future.

We retrieved drug targets potentially relevant to COVID-19 from three resources (Figure 1 ): 1) target genes of 11 drugs under trials for COVID-19 treatment from ClinicalTrials.gov (Supplementary Table 1) ; 2) 332 human proteins interacting with SARS-CoV-2 proteins in human cell lines (8) ; 3) 44 genes associated with SARS-CoV in a mouse model (9) . After removing duplicates, 380 unique targets were selected (Supplementary Table 2 ). The genetic predictors (instruments) for the 380 target genes in 11 SARS-CoV-2 related tissues were extracted from 4 recent expression and protein quantitative trait locus (eQTL and pQTL respectively) studies (3)(10)(11) (12) . From these studies 1493 instruments for 353 drug targets were available for our proteome/transcriptome-wide association analysis (Supplementary Table  3 ), while the remaining 27 targets have no robustly associated genetic variants.

The target-disease atlas of the 353 drug targets was built using two-sample MR (13)(14) and colocalization analysis (15) , evaluating evidence for their causal effects on 49 viral infection phenotypes, 501 complex diseases and 72 disease related phenotypes (Supplementary Table 4) . 45 ,590 target-disease associations were tested in plasma proteome and transcriptome in whole blood (P< 1.1x10 -6 at a Bonferroni-corrected threshold). Where data was available, we also tested the tissue-specific effects of gene expression of the same targets on the outcome phenotypes. Overall, 372,482 target-disease associations were estimated in the 11 COVID-19 relevant tissues (see the list of tissues in Methods). Overall, we observed 833 target-disease associations with robust MR evidence in the 11 tested tissues. 726 of the 833 (87.2%) associations also showed strong colocalization evidence (colocalization probability > 70%) (Supplementary Table 5 , 6, 7 and 8), making these the most reliable findings of this study. Of these, 366 associations were obtained using a single cis instrument in a Wald ratio model (16) , 327 were obtained using a single trans instrument and 33 were estimated using multiple instruments in an inverse variance weighted (IVW) model (17) . The remaining 107 (12.8%) associations had evidence from MR but did not have strong evidence of colocalization (probability<70%; Supplementary Table 9 ), emphasizing the importance of this approach to address confounding by linkage disequilibrium (LD) in phenome-wide association studies.

Findings from our target-disease atlas can be used to conduct hypothesis-driven investigations of tissue-dependent effects of target expression on certain diseases. Figure 2 illustrates the effects of target expression in different tissues on four diseases from our atlas: Crohn's disease (A); hypertension (B); hay fever, allergic rhinitis or eczema (C); and diabetes (D). Tissue-specific associations were observed between 11 to 17 of the target genes and these four diseases (Supplementary Table 10 ). Since these target genes that encode COVID-19interacting proteins also appear to have causal effects on these diseases, it would be important to carefully assess their potential beneficial and/or adverse effects on these complex diseases in any future drug target prioritization for COVID-19.

In the analysis of the association between the 353 drug targets and 49 viral infection phenotypes, we identified 2 associations with robust MR (P<1.1x10 -6 ) and colocalization evidence (probability >70%) using gene expression data in whole blood, including NEU1 associated with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2020. . chronic hepatitis and DPY19L1 associated with viral enteritis. Three additional drug targets were suggestively associated with 3 viral infection phenotypes (P<1x10 -3 ) (Supplementary Table 5 ). This included JAK2 (the target gene for a marketed drug, Baricitinib) associated with chronic hepatitis.

In the primary analysis in plasma proteome and whole blood transcriptome, we identified 45 potential causal effects of protein levels on disease traits (Supplementary Table 6 ) and 430 potential causal effects of transcript levels on disease traits (Supplementary Table 7) , with both MR and colocalization evidence. These 475 causal estimates included 95 targets on 105 diseases and disease related phenotypes. Figure 3 illustrates the MR results of gene expression level of the JAK2 gene on 501 complex diseases and 72 phenotypes using whole blood data from the eQTLGen consortium. In this example, the gene expression level of JAK2 was predicted to influence 9 diseases/phenotypes (Supplementary Table 7) , such as atopy, Type 1 diabetes, inflammatory bowel disease and obesity, which suggested that this target gene is potentially pleiotropic.

As a follow-up analysis, we further identified 249 potential tissue-dependent causal effects of target on disease with robust MR and colocalization evidence. This covered 52 unique genes based on instruments for expression in 7 tissues against 47 unique diseases (Supplementary Table 8 ). Among the 29 tissue-dependent effects of target on disease with robust MR and colocalization evidence in more than one tissue, 27 of them showed the same direction of effect across whole blood and multiple other tissues. Only the genetically instrumented gene expression level of KPNA1 and SRP19 in whole blood and in testis showed opposite direction of effects against diastolic blood pressure and heel bone mineral density respectively. Figure 4 illustrates an example of the tissue-dependent effect of DHODH gene on low-density lipoprotein cholesterol (LDL-C). Inhibition of DHODH gene is the functional mechanism of a marketed drug, Leflunomide. This drug has been suggested as a potential treatment for COVID-19 (18) (19) . In our MR analysis, we observed that the expression level of DHODH was specifically associated with LDL-C, which means it did not suffer a major issue of pleiotropy across the phenome. Moreover, the expression level of DHODH in a wide range of tissues (e.g. lung, testis and colon, in which the SARS-CoV-2 receptor angiotensin converting enzyme II (ACE2) is also highly expressed) were all found to be positively associated with LDL-C.

We further integrated the 726 target-disease MR associations with clinical trial information from Open Targets (20) , ChEMBL (21), DrugBank (22) , Drug-gene-interaction (DGI) (23), the druggable genome (24) and ClinicalTrial.gov to prioritise drug targets against COVID-19. The 726 associations were further scored based on their putative causal evidence across multiple tissues and their druggability. More specifically, 4 categories of scores were setup for the prioritisation, including omics score, infection score, trial score and druggability score. Each of the scores was scaled between 0 and 1 (Supplementary Table 11 ). Of the 726 target-disease associations, only 499 of them were unique target-disease pairs (due to the same pair appearing in multiple tissues). Two of the 499 associations received high scores in three of the four . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2020. . categories (making these the highest priority targets), while 77 scored highly in two categories, and 97 scored highly in one category. 323 of the original 499 associations had low scores in all categories and are therefore lowest priority (Supplementary Table 12 ). The top 5 target genes were DHODH, ITGB5, JAK2, TFRC and POR, scoring 1 in at least two categories and more than zero in at least one other category. ITGB5 is the target for Cilengitide, which was primarily developed for treating cancers such as glioblastoma. Our study prioritised this target in three categories (omics score=1, druggable score=1, trial score=0.75, infection score=0), which implies that it merits further investigation as a potential target for COVID-19 treatment. In addition, genetically predicted ITGB5 transcript levels across multiple tissues showed a consistent negative association with three blood pressure phenotypes, which suggests antihypertensive potential. None of the 5 top targets were strongly associated with potentially acute comorbidities for COVID-19 treatment such as cardiac dysrhythmias or allergic diseases (excepting the potential beneficial effect of JAK2 on allergic diseases), which would have raised concerns about their suitability as COVID-19 targets.

As a contrasting example, TLR9, the target for a marketed drug, Hydroxychloroquine, showed druggable evidence (druggable score=1, trial score=1) but with a low score for MR evidence across omics/tissues (omics score=0, infection score=0). Despite the reported antiviral activity of Chloroquine against COVID-19 in vitro (25), a recent study emulating a target trial suggested no evidence of any antiviral activity or clinical benefit combining Hydroxychloroquine and Azithromycin for the treatment of severe COVID-19 patients (26) . A recent systematic review and meta-analysis of observational evidence also suggested no clinical benefits of Hydroxychloroquine for treatment of COVID-19 patients (27) . In addition to the efficacy concerns previously raised for Hydroxychloroquine, our phenome-wide MR results further suggested that reduced TLR9 expression increases risk of cardioembolic stroke, asthma and some immune related diseases (Supplementary Table 13 ), consistent with some concerns previously expressed in the literature (28) .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. .

Genetic methods such as MR and colocalization provide a rapid and cost-effective approach to prioritise drug targets in the early stages of drug development (3)(29), providing an indication of efficacy and potential on-target beneficial or adverse effects (30) (31) . In this study, we integrated a list of 380 coronavirus-related drug targets from COVID-19 trials and in vitro experiments. We pooled data on genetic associations with these drug targets from 4 recent molecular phenotype genome-side association studies (GWASs) (3)(10)(11)(12), identifying 353 drug targets for which there were reliable genetic predictors which could be used as instruments in MR. By applying tissue-specific MR of gene expression and plasma protein levels, we were able to estimate the causal effects of these targets on 49 viral infection phenotypes, 501 complex diseases and 72 disease related phenotypes, in total estimating 372,482 effects. Of these, potentially causal effects in 726 target-phenotype pairs were estimated with robust MR and colocalization evidence. These results provide evidence of on-target safety issues and/or beneficial effects of the COVID-19 drug targets. To enable this evidence to be widely accessible for drug target research, we constructed an open access browser allowing rapid queries of the drug targets, genetic predictors of the target genes and the disease atlas (http://epigraphdb.org/covid-19/ctda/).

This study supports drug target prioritization for treatment of COVID-19 and other diseases in three ways: 1) investigating potential on-target safety issues for approved drugs under trials for COVID-19 treatment; 2) prioritizing drug targets that merit further evaluation for COVID-19; 3) identifying tissue-specific effects of the drug targets on the human phenome.

First, our study provides evidence of the potential on-target safety issues of marketed drugs in trials for COVID-19 treatment. For example, Baricitinib, a cyclin G-associated kinase inhibitor, has been suggested as a drug for COVID-19 treatment (32) and is now in trials for efficacy evaluation (CTID: NCT04320277). It was proposed to reduce systemic inflammation by inhibiting JAK2 protein. In our study, we observed a putative causal effect of JAK2 expression on chronic hepatitis, which aligned with literature evidence of hepatitis B reactivation following ruxolitinib treatment (inhibitor of JAK2) (33) . Our phenome-wide association analysis further suggested that reducing the gene expression of JAK2 was not strongly associated with increased risk of acute conditions (cardiac dysrhythmias or allergic diseases). Although JAK2 reduction may increase weight and risk of inflammatory bowel disease, potential Baricitinib use for COVID-19 treatment will be short-term, and these side effects are probably inconsequential.

Second, our prioritization approach highlighted three drugs with potential for COVID-19 treatment, including Leflunomide (target: DHODH), Cilengitide (target: ITGB5), and E2.3 (under Phase I trial, target: TFRC). Leflunomide is an immune suppressive drug used for autoimmune diseases, such as rheumatoid arthritis (34) . It also showed antiviral effect against a wide range of DNA and RNA viruses, such as herpes simplex virus (35) (19) . In addition, our MR finding suggested the lipid lowering potential of Leflunomide use, which merits further investigation. For Cilengitide (ITGB5), our MR analyses suggested that reduced gene expression level of ITGB5 showed a consistent effect on lowering systolic and diastolic blood pressure level and lowering hypertension risk. This implies its potential anti-hypertensive effect. Hypertension has been suggested as a potential risk factor for complications of COVID-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. . 19 (41) . Cilengitide could be a promising candidate drug for COVID-19 treatment with antihypertensive potential as well.

Third, the tissue-specific results suggested that expression levels of some targets across multiple tissues were associated with the same phenotypes, while some other targets showed apparent tissue-specific effects on diseases/phenotypes. For example, expression levels of DHODH and ITGB5 in multiple tissues showed similar causal effects on LDL-C and blood pressure respectively. When designing trials based on these drug targets, careful pre-clinical investigation is needed to understand the tissue-specific mechanisms of the targets on tested indications.

Some limitations of our analysis are worth noting. Whilst initiatives are underway to collect genetic information for COVID-19 patients (e.g. the COVID-19 host genetics initiative, https://covid-19genehostinitiative.net/) and in the UK Biobank (42) , no such GWAS of COVID- 19 phenotypes has yet been performed. Our evaluation of potential targets therefore excludes estimated effects of these targets on COVID-19 disease risk or progression. In the near future such data is likely to become available in a number of large-scale population-based biobanks across the world, including the UK Biobank, China Kadoorie Biobank (43), HUNT study (44), FinnGen (https://www.finngen.fi/fi), DeCODE (https://www.decode.com/) and the Million Veteran Program (45) . These biobanks are designed to study long-term health conditions, but with data linkage between these biobanks and electronic health records and/or COVID-19 data (as has recently happened with UK Biobank), these biobanks could be tremendous resources to rapidly generate genetic association data in epidemic and pandemic situations. The recent initial GWAS of COVID-19 found no GWAS hits, which highlight the importance of seriously considering potential bias of the data. When the unbiased data are available, the drug target information and the genetic predictors of the 353 drug targets we curated in this study as well as the drug target prioritization pipeline could provide even more valuable insights into the potential drug targets for infectious disease treatment. A second limitation is that the drug targets evaluated in this study were proxied using a limited number of instruments, which means the putative causal effects rely on one or two genetic instruments. Even though our results suggest some biological links between the target and diseases, these only provide evidence for the very first step of the drug development process. Finally, whilst these are plausible targets for COVID-19, we can't predict whether successful intervention would impact on risk of infection, progression/severity of disease or other disease characteristics relevant to public health (e.g. viral shedding).

In conclusion, this study identified 726 putatively causal effects between the 353 COVID-19 related targets and the human phenome using MR and colocalization approaches. These associations support causality but do not prove it, as horizontal pleiotropy remains an alternative possibility. Our study provides both a statistical genetics pipeline and an openly available platform to prioritise potential COVID-19 targets on the basis of MR and existing trial evidence. The platform also evaluated repurposing opportunities for approved drugs on other indications. Our approach and platform will provide additional value once genetic association studies of COVID-19 are available in the near future.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. .

In this study, drug targets against COVID-19 were selected from three resources: i) a list of 11 drugs under trials for COVID-19 treatment were extracted from ClinicalTrials.gov (https://clinicaltrials.gov/ct2/results?cond=COVID-19;). 10 of these 11 drugs were mapped to their target genes using Drug-Gene-Interaction (DGI) database (http://dgidb.org/) (23) and CHEMBL database (21) (Supplementary Table 1) ; ii) 332 human proteins interacting with SARS-CoV-2 proteins from Gordon et al. (8) ; iii) 44 genes associated with SARS-CoV from Gralinski et al. (9) . After de-duplicating these, 380 unique drug targets were selected for our study (Supplementary Table 2) .

Next, gene and protein expression levels of these targets were looked up from four resources: protein expression levels in plasma from four studies (29)(46)(47)(48) implemented in Zheng et al. (3), gene expression levels in whole blood from eQTLGen consortium (10), tissue specific gene expression levels in 7 tissues from the GTEx consortium (11) and gene expression levels in two kidney tissues from Gilles et al. (12) . After the mapping step, 353 drug targets with genetic variants robustly associated with the transcripts and/or proteins were included as the start point of the instrument selection (Supplementary Table 2 ).

The genetic variants, genes and proteins were further mapped to genome build GRCh37.p13 coordinates and we used the following criteria to select genetic instruments:

1. We selected SNPs that were associated with any protein or gene expression (using a Pvalue threshold ≤ 5x10 -8 ) in at least one of the four GWASs, including both cis and trans instruments. 2. We then conducted LD clumping for the instruments with the TwoSampleMR R package (14) to identify independent instruments for each protein/gene. We used r 2 < 0.001 as the threshold to exclude correlated instruments in the cis (or trans) gene region. After instrument selection, 1493 instruments were kept for the genetic analyses of this study (Supplementary Table 3) .

We split instruments into two groups: 1) 1269 cis-acting instruments within a 500Kb window from each side of the leading pQTL of the protein/gene; 2) 224 instruments outside the 500Kb window of the leading pQTL were designated as trans instruments. Whilst trans instruments may be more prone to pleiotropy, their inclusion could increase statistical power as well as the scale of the study. Therefore, for the proteins and genes with cis instruments or trans instruments, we conducted MR analyses using both sets of instruments (Supplementary Table 3 ).

We obtained effect estimates for the association of the proteins and genes with viral infection phenotypes and complex human phenotypes using GWAS summary statistics which were obtained from the GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics) (49) , IEU GWAS database (http://gwas.mrcieu.ac.uk/) (14) and SAIGE UK Biobank data release . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. .

(https://www.leelabsg.org/resources) (50) . We used the following inclusion criteria to select complex phenotypes to be analysed:

1. The GWAS with the greatest expected statistical power (e.g. largest sample size or number of cases) when multiple GWAS records of the same disease or quantitative phenotype were available. 2. GWAS with effect sizes, standard errors and effect alleles for all tested variants (i.e. full GWAS summary statistics available). After selection, 49 viral infection phenotypes and 501 complex diseases were defined as primary outcomes. 72 quantitative phenotypes were defined as secondary outcomes (Supplementary Table 4 ).

Mendelian randomization analysis In the initial MR analysis, 55 instruments of 39 plasma proteins (N=3,301) and 833 instruments of 331 gene transcripts in whole blood (N=31,684) were used as the exposures to proxy the effect of the 353 drug targets for COVID-19 (Supplementary Table 3) , which maximized the statistical power of the study and supported us to obtain an overall view of the target-phenotype associations across multiple disease areas. 49 viral infection phenotypes, 501 complex diseases and 72 quantitative phenotypes were used as the outcomes. Due to missingness of available exposure or outcome data, the causal relations of 353 targets on 622 human phenotypes were tested in this study. We selected a P-value threshold of 0.05, corrected for the number of independent tests, as our threshold for prioritising MR results for follow up analyses (number of tests= 45,590; P< 1.1x10 -6 ). The Wald ratio (16) method was used to obtain MR effect estimates for targets with only one instrument, where the Wald ratio MR effect estimates were sensitive to the particular choice of instrument. For targets with two or more instruments, the IVW method (17) was used to estimate the causal effects.

Results that survived the Bonferroni corrected threshold (P< 1.1x10 -6 ) in the MR analysis were evaluated using colocalization analysis, which estimates the posterior probability of each genomic locus containing a single variant affecting both the target and the phenotype (15) . The prior probabilities that a variant is equally associated with each phenotype (p1=1×10 -4 ; p2=1×10 -4 ) and both phenotypes jointly (p12=1×10 -5 ) were used for this analysis. A posterior probability of > 70% for the colocalization hypothesis in this analysis would suggest that the two association signals are likely to colocalize within the test region (noted as "Colocalised"). The same colocalization approach was applied to cis-and trans-instruments. In addition, we conducted an approximate colocalization analysis (called LD check), in which the LD between the sentinel variant of each target and the 30 strongest SNPs in the region associated with the phenotype were checked. LD r 2 > 0.7 between the sentinel variant and any of the 30 SNPs associated with the phenotype was used as evidence of colocalization (noted as "LD Check"). The rest of the targetphenotype associations were noted as "Not colocalised".

The functional receptor of SARS-CoV-2, ACE2 (51), is highly expressed in multiple organs, including gastrointestinal tract, gallbladder, testis, and kidney. This is consistent with the fact . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. . that whilst SARS-CoV-2 infection primarily manifests with acute respiratory illness, SARS-CoV-2 can also be detected in faeces (52) and kidney tubules (53) . The presence of SARS-CoV-2 in the alimentary tract for longer than in the respiratory system (54) suggests that the intestine may be a hidden reservoir of SARS-CoV-2. We therefore set out to explore differences in potential target effects in different tissues. In order to understand the tissue specific effects of the candidate targets of COVID-19 on human phenotypes, we selected the 9 tissues in which ACE2 is highly expressed, including testis, lung, kidney cortex, kidney glomerular, kidney tubulointerstitial, stomach, colon transverse, small intestine terminal ileum and colon sigmoid.

Tissue specific gene expression data of the 353 targets in each selected tissue were obtained from two studies: GTEx V8 and Gillies et al (11) (12) . After selection, 580 instruments of 218 gene transcripts were selected in the 9 tissues, which included 141 instruments for 132 gene transcripts in testis, 125 instruments for 115 transcripts in lung, 20 instruments for 20 transcripts in kidney cortex, 6 instruments for 6 in kidney glomerular, 8 instruments for 8 transcripts in kidney tubulointerstitial, 71 instruments for 67 transcripts in stomach, 84 instruments for 81 transcripts in colon sigmoid, 98 instruments for 96 transcripts in colon transverse and 41 instruments for 39 transcripts in small intestine terminal ileum (Supplementary Table 3 ). The same MR and colocalization analysis pipeline were applied for the tissue specific analysis.

The MR analyses (including Wald ratio, single SNP MR, IVW) were conducted using the MR-Base TwoSampleMR R package (github.com/MRCIEU/TwoSampleMR) (14). The MR results were plotted as Manhattan plots and forest plots using code derived from the ggplot2 package in R (https://cran.r-project.org/web/packages/ggplot2/index.html).

For the 154 drug targets with suggestive MR and colocalization evidence (P of MR < 1x10 -5 and colocalization probability >70%), we mapped the drug targets with related drug names using four platforms: OpenTargets (20) , ChEMBL (21), DrugBank (22) and DGI platforms (23) . After this analysis, we mapped 40 targets to their targeted drugs (Supplementary Table 14) . The trial information of these 40 drugs were further looked up from ClinicalTrial.gov or WHO ATC (https://www.whocc.no/atc_ddd_index/) websites, which includes the indication, the trial status (recruiting or completed), the action type of the drug (inhibitor or antagonist), the ClinicalTrial.gov ID (CTID) or ATC ID and maximum trial phase.

We further mapped the targets to the previously reported "druggable genome" (24) . This study stratified the potential drug targets from across the genome into three tiers. Tier 1 (1427 genes) included efficacy targets of approved small molecules and biotherapeutic drugs, as well as targets modulated by clinical-phase drug candidates; tier 2 was composed of 682 genes encoding proteins closely related to drug targets, or with associated drug-like compounds; and tier 3 contained 2370 genes encoding secreted or extracellular proteins, distantly related proteins to approved drug targets. For the COVID-19 drug targets, 16 targets were mapped to tier 1, 4 targets to tier 2 and 17 targets to tier 3 (Supplementary Table 12) .

For the 726 target-disease associations with suggestive MR and colocalization evidence, we prioritised the COVID-19 related drug targets by four separate categories of scores: 1) Omics . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. . score (0 or 1), which estimates whether a specific target-disease association showed robust MR evidence in both proteome and transcriptome levels or in more than one tissue; 2) Infection score (0 or 1), which refers to whether the target showed strong association with at least one of the viral infection phenotypes we tested; 3) Druggable score (0 to 1), which refers to the druggability of the target (data from Finnan et al); 4) Trial score (0 to 1), which refers to the trial stage of the target (e.g. Pre-clinical to Phase 4). More details of the score system is listed in Supplementary  Table 11 .

We have made all results openly available to browse or download at the COVID-19 Target-Disease Atlas (CTDA) browser within the EpiGraphDB platform (http://epigraphdb.org/covid-19/ctda/). This includes 372,482 unique target-disease associations evidence for 353 targets on 622 diseases/phenotypes in 11 SARS-CoV-2 related tissues. Users are able to query the study results by the targeted gene name, outcome disease name, and the tissues via the online platform, and the results are presented in searchable tables as well as volcano plots. In addition, users can programmatically access the results using the /covid-19/ctda endpoints in the application programming interface (API) of EpiGraphDB via http://api.epigraphdb.org/.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. .

TableS1. Drugs in trials for COVID-19 treatment and their target genes.

TableS2. The available genetic information for SARS-CoV-2 target genes from pQTL and tissue specific eQTL resources.

TableS3. The genetic predictors and association information of the SARS-CoV-2 target genes.

TableS4. The list of human phenotypes been used as outcomes for the omics study.

Note: The target-infection disease associations with Mendelian randomization p value < 10 -3 were included in this table.

TableS6. The plasma protein-phenotype associations with strong MR and colocalization evidence.

Note: The target-disease associations passed Bonferroni corrected threshold (1.1x10 -6 ) and with robust colocalization evidence (probability > 70%) were included in this table.

Note: The target-disease associations passed Bonferroni corrected threshold (1.1x10 -6 ) and with robust colocalization evidence (probability > 70%) were included in this table.

TableS8. The tissue-specific gene expressions-phenotype associations with strong MR and colocalization evidence.

Note: The target-disease associations passed Bonferroni corrected threshold (1.1x10 -6 ) and with robust colocalization evidence (probability > 70%) were included in this table.

TableS9. The target-disease associations with strong MR evidence but without strong colocalization evidence.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 11, 2020. . Note: The target-disease associations passed Bonferroni corrected threshold (1.1x10 -6 ) but without robust colocalization evidence (probability < 70%) were included in this table.

Note: The target-phenotype associations counted in this table were associations passed Bonferroni corrected threshold (1.1x10 -6 ) and with robust colocalization evidence (probability > 70%).

TableS11. The score system been used to prioritize drug targets for COVID-19.

Note: Four categories of scores were setup, including omics score, infection score, trial score and druggability score. Each of the scores was scaled between 0 and 1.

Note: For each target-phenotype association, its four scores were listed in this table together with its drug trial information.

TableS13. The top target-phenotype association for one drug target gene TLR9.

Note: The exposure here is the gene expression level of TLR9 in blood and testis, the outcomes were human phenotypes, the association beta, standard error and p value were reported in this table.

TableS14. The triangulation table mapping drug target gene with drug name, the drug trial and druggability information.

Note: The target genes were mapped to the drugs using DGI, OpenTargets, ChEMBL and/or Drugbank databases. The drug trial information for each drug was identified from DGI, OpenTargets, ChEMBL, Drugbank and/or ClinicalTrial.gov. The druggability information were extracted from Finan et al (24) .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2020. . The four forest plots refer to the MR associations of Crohn's disease (A), hypertension (B), hay fever/allergic rhinitis or eczema (C) and diabetes (D). The X-axis is the odds ratio of the MR estimates.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2020. . 

Disciplined approach to drug discovery and early development

The support of human genetic evidence for approved drug indications

Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases

A transcriptome-wide Mendelian randomization study to uncover tissue-dependent regulatory mechanisms across the human phenome

Compassionate Use of Remdesivir for Patients with Severe Covid-19

No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross

Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis

The GTEx Consortium atlas of genetic regulatory effects across human tissues

An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome

Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?

Bayesian test for colocalisation between pairs of genetic association studies using summary statistics

Mendelian randomization: using genes as instruments for making causal inferences in epidemiology

Mendelian randomization analysis with multiple genetic variants using summarized data

The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic

Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2. 2020

Open Targets: a platform for therapeutic target identification and validation

ChEMBL: towards direct deposition of bioassay data

DrugBank: a comprehensive resource for in silico drug discovery and exploration

DGIdb 3.0: a redesign and expansion of the drug-gene interaction database

The druggable genome and support for target identification and validation in drug development

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

Hydroxychloroquine Versus COVID-19: A Rapid Systematic Review and Meta-Analysis. medRxiv

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Genomic atlas of the human plasma proteome

Mendelian randomization in cardiometabolic disease: challenges in evaluating causality

Mendelian Randomization as an Approach to Assess Causality Using Observational Data

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

Leflunomide for the treatment of rheumatoid arthritis and autoimmunity

Leflunomide in Solid Organ Transplantation and Polyoma Virus Infection

Social responsibility, personal responsibility, and prognosis in public judgments about transplant allocation

Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778

Leflunomide inhibition of BK virus replication in renal tubular epithelial cells

Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system

Antiviral activity of A771726, the active metabolite of leflunomide, against Junín virus

Mild or Moderate Covid-19

UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age

China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up

The Nord-Trøndelag Health Study 1995-97 (HUNT 2). Norsk epidemiologi

Million Veteran Program: A mega-biobank to study genetic influences on health and disease

Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease

Connecting genetic risk to disease end points through the human blood plasma proteome

Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease

The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019

Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies

A pneumonia outbreak associated with a new coronavirus of probable bat origin

First Case of 2019 Novel Coronavirus in the United States

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. 2020

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples